For those who are unfamiliar with SARMS, let me fill you in. SARMS, which is short for selective androgen receptor modulators, are a new class of drugs designed to provide the anabolic (i.e. tissue building) benefits of steroids, but without the androgenic, estrogenic, and in many cases, cardiovascular side effects typically associated with general AAS. This means you don’t have to deal with unwanted issues like gynecomastia (enlarged nipples), water retention, prostate problems, hair loss/growth, acne, oily skin, emotional issues, etc. Depending on the dose administered, they even have a very little effect on the HPTA, resulting in decreased suppression of natural testosterone production. Consequently, PCT is a easy and quick and recovery time is minimum.
Enter GAIN (LGD4033). Having recently completed Phase I human clinical trials, a mandatory step in the FDA approval process, GAIN (LGD-4033) was found to be well tolerated, demonstrating no adverse events among test subjects. In terms of anabolic potential GAIN (LGD-4033) performed impressively, resulting in significant increases in muscle size and strength within a short period of time. By all accounts, GAN (LGD-4033) appears to be a success, with a huge amount of positive user reviews since its release onto the peptide market.
In order to see more clearly what GAIN (LGD-4033) is all about, let’s take a look at the highlights of this first round of clinical trials. Being an 8 man (6 active, 2 placebo), single dose escalation study, each participant was provided with a different dose of GAIN (LGD-4033). The dosages administered to the test subjects were .1 mg, 1 mg, 5 mg, 10 mg, 15 mg, and 22 mg for 2 weeks consecutively, during which time it was evaluated for both safety and tolerability.
As any experienced steroid user knows, the effects of AAS on cardiovascular health markers, such as hematocrit, blood pressure, hemoglobin, and lipids, are a major area of concern for anyone wishing to maintain good cardiovascular health. With traditional AAS causing elevations in all of these markers, often times into a dangerous range, finding a SARM. capable of avoiding these adverse fluctuations has been a priority among researchers.
Fortunately, GAIN (LGD-4033) passes with flying colours, with study results showing no change in blood pressure, hematocrit, hemoglobin, or lipids. However, it should be noted that at doses above 5 mg/day, HDL (good) cholesterol levels were lowered below the standard reference range, although they returned to normal upon stopping the drug. The inability of GAIN (LGD-4033) to affect hematological health markers eliminates the possibility of SARM induced heart attack/stroke—something modern day steroids user have had to contend with quite a bit lately.
The effect of GAIN (LGD-4033) on testosterone levels is a bit more varied. At dosages below 5 mg/day, total testosterone levels remained within the standard reference range (270-1070 ng/dl), while dosages above 5 mg/day reduced total testosterone slightly. However, this does not mean that GAIN (LGD-4033) at dosages below 5 mg/day have no effect on testosterone production. It simply means that this dosing range prevented the test subjects from falling into clinical deficiency, but for those who are familiar with the flaws of this reference range, it brings little reassurance regarding the drug’s safety in terms of HPTA maintenance.
In reality, GAIN (LGD-4033) caused a linear decrease in total testosterone levels from baseline at all dosages levels, but the researchers’ claim that this decrease fails to merit statistical significance simply because testosterone levels did not drop below 270 ng/dl, is unintentionally deceptive. This means that someone’s testosterone level could have dropped from 800 ng/dl to 350 ng/dl, yet this massive drop would have been ignored simply because the individual did not end up in a clinically deficient range (-270 ng/dl). However, these results are still significantly better than traditional AAS, as just about all steroids, when administered at effective dosages, tend to result in clinical deficiency within just a few weeks. The fact that the test subjects also made a quick recovery implies that LGD-4033’s suppressive effect on the HPTA is not nearly as long-lasting as AAS and a much safer option.
Unlike most oral steroids, GAIN (LGD-4033) is non-methylated and therefore lacks the liver toxicity typically present with methylated AAS. Confirmation was obtained when researchers evaluated liver function at both baseline and mid-study, revealing no meaningful alterations in liver readings. This advantage over oral AAS, in combination with minimal hematological disturbances, effectively lifts the cycle duration restrictions encountered with traditional orals. In other words, this SARM. can be cycled long-term without fear of hepatic dysfunction/injury.
Most men, at some point in their life, end up experiencing prostate enlargement, as well as elevated PSA readings. This is not a big deal if controlled, but can become serious if allowed to get out of hand. Steroids contribute to the problem by attaching to and activating receptor sites within the prostate, promoting hypertrophy and exacerbating any conditions which may be present, such as prostate cancer. For those of you that are getting older or who currently suffer from prostate problems, you will be happy to learn that GAIN (LGD-4033) has no effect on PSA readings, due to its high degree of selectivity for muscle over the prostate and other organs/systems.
GAIN (LGD-4033) also has an antiresorptive effect in bone, preventing the release of minerals back into the bloodstream. This is especially beneficial for those diagnosed with osteoporosis. Sebaceous glands, cortisol levels, and heart function (ECG) also appears to be unaffected.
Like with AAS, gains with GAIN (LGD-4033) are dose-dependent, allowing the individual to tailor their dose according to need. While doses up to 22 mg/day were shown to be safe and well effective, it is difficult to know what dosing range BB’rs will end up at, given their history of pushing things to the limit. With a half-life of roughly 30 hours, once daily dosing is ideal for maintaining steady concentrations of this drug within the bloodstream.
In conclusion, GAIN (LGD-4033) does exactly what a SARM. is supposed to do—provide strong anabolic effects without any significant external or internal side effects. Its mild nature makes it a great drug for beginners or for anyone else looking to improve their physique with minimal risk to their health, as well as for women who want to avoid the masculinizing effects of traditional anabolics. It can also be stacked with AAS and/or other SARMS in order to further boost muscle growth without placing additional stress on the body.
To purchase GAIN (LGD-4033) please visit the following link: GAIN (LGD-4033)